Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Effect of Semaglutide Versus Placebo on the Progression of Renal Impairment in Subjects With Type 2 Diabetes and Chronic Kidney Disease

Next Previous
Trial Profile

Effect of Semaglutide Versus Placebo on the Progression of Renal Impairment in Subjects With Type 2 Diabetes and Chronic Kidney Disease

Status: Discontinued
Phase of Trial: Phase III

Latest Information Update: 13 Jun 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Semaglutide (Primary)
  • Indications Cardiovascular disorders; Renal failure; Type 2 diabetes mellitus
  • Focus Adverse reactions; Registrational
  • Acronyms FLOW
  • Sponsors Novo Nordisk

Most Recent Events

  • 10 Jun 2025 According to Novo Nordisk media release, data from this study will be showcased at the upcoming American Diabetes Association (ADA) 85th Scientific Sessions taking place in Chicago, June 20 -23, 2025.
  • 28 Jan 2025 According to Novo Nordisk media release, Richard E. Pratley, MD, Medical Director at the AdventHealth Diabetes Institute Orlando, FL, is the Co-Chair of the FLOW Trial.
  • 28 Jan 2025 According to Novo Nordisk media release, the USFDA has approved Ozempic (Semaglutide) to reduce the risk of kidney disease worsening, kidney failure (end-stage kidney disease), and death due to cardiovascular disease in adults with type 2 diabetes and chronic kidney disease (CKD), based on the results of this pivotal phase 3b "FLOW" trial.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top